DRRX - デュレクト (DURECT Corporation) デュレクト

 DRRXのチャート


 DRRXの企業情報

symbol DRRx
会社名 Durect Corp (デュレクト)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダレクト(Durect Corporation)は研究と開発に従事するバイオ医薬企業である。同社の候補製品は代謝/脂質障害向けの経口薬DUR-928、急性臓器傷害の注射可能薬DUR-928を含む。同社の他の製品候補はPOSIMIR(ブピバカインの制御放出注入)、REMOXY(経口制御放出オキシコドン)、ORADUR-ADHD、ELADUR(経口制御放出オキシコドン)、Relday(リスペリドン)、ORADURベースのオピオイド(ヒドロモルホン)、SABREベースの眼科薬を含む。同社のALZET製品ラインはマウス、ラットおよび他の実験動物の研究に使用される小型の移植可能な浸透圧ポンプと付属品を提供する。同社は製薬と医療機器クライアントの製品原材料に応用する標準およびカスタム生分解性ポリマーと賦形剤の生産と販売を行う。   デュレクトは米国の医薬品会社。慢性痛、術後疼痛、統合失調症、躁うつ症、注意欠陥多動性障害の治療薬に焦点を置く。「レモキシ―(経口オキシコドン)」、「ポジデュア(ブピバカイン注射剤)」、「エラデュア(経皮吸収ブピバカイン)」、リスペリドン系抗精神病薬、「オラデュア」の治験を行う。  DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
本社所在地 10260 Bubb Road Cupertino CA 95014 USA
代表者氏名 Felix D Theeuwes フェリックス・テューウィーズ
代表者役職名 Chairman Chief Scientific Officer
電話番号 +1 408-777-1417
設立年月日 35827
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数
url www.durect.com
nasdaq_url https://www.nasdaq.com/symbol/drrx
adr_tso
EBITDA EBITDA(百万ドル) 0.69000
終値(lastsale) 1.07
時価総額(marketcap) 173341767.64
時価総額 時価総額(百万ドル) 168.48170
売上高 売上高(百万ドル) 47.18500
企業価値(EV) 企業価値(EV)(百万ドル) 145.94370
当期純利益 当期純利益(百万ドル) -0.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 DURECT Corporation revenues decreased 22% to $6.9M. Net loss decreased 15% to $15.3M. Revenues reflect Product Revenues net decrease of 28% to $5.2M. Lower net loss reflects Other Research and development decrease of 22% to $12.4M (expense) Selling and general decrease of 13% to $5.4M (expense) Interest and other income increase from $75K to $398K (income).

 DRRXのテクニカル分析


 DRRXのニュース

   Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 22:55:07 Zacks Investment Research
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:08 Zacks Investment Research
Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis  2020/01/02 14:00:00 PR Newswire
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   DURECT (NASDAQ:DRRX) Stock Price Down 5.9%  2019/11/15 05:59:36 Modern Readers
DURECT Co. (NASDAQ:DRRX) was down 5.9% during trading on Thursday . The stock traded as low as $1.89 and last traded at $1.91, approximately 652,300 shares changed hands during mid-day trading. A decline of 18% from the average daily volume of 792,295 shares. The stock had previously closed at $2.03. Several equities research analysts have […]
   Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 22:55:07 Zacks Investment Research
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:08 Zacks Investment Research
Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis  2020/01/02 14:00:00 PR Newswire
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   DURECT (NASDAQ:DRRX) Stock Price Down 5.9%  2019/11/15 05:59:36 Modern Readers
DURECT Co. (NASDAQ:DRRX) was down 5.9% during trading on Thursday . The stock traded as low as $1.89 and last traded at $1.91, approximately 652,300 shares changed hands during mid-day trading. A decline of 18% from the average daily volume of 792,295 shares. The stock had previously closed at $2.03. Several equities research analysts have […]
   Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 22:55:07 Zacks Investment Research
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:08 Zacks Investment Research
Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis  2020/01/02 14:00:00 PR Newswire
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   DURECT (NASDAQ:DRRX) Stock Price Down 5.9%  2019/11/15 05:59:36 Modern Readers
DURECT Co. (NASDAQ:DRRX) was down 5.9% during trading on Thursday . The stock traded as low as $1.89 and last traded at $1.91, approximately 652,300 shares changed hands during mid-day trading. A decline of 18% from the average daily volume of 792,295 shares. The stock had previously closed at $2.03. Several equities research analysts have […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デュレクト DRRX DURECT Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)